Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain study reveals how inflammation may steal joy in aging adults

NCT ID NCT05363527

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how inflammation affects feelings of pleasure and motivation in older adults (ages 60-80) with anxiety. Researchers used brain scans and computer tasks to measure reward responses. The goal was to better understand the link between anxiety, inflammation, and depression in aging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

40 people

The number who actually took part.

Started

Mar 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants will be required to be in good general health (as evaluated during the phone and in-person baseline session) * Participants will be aged 60 to 80 years. * 3/4 the participants (n=30) will be those with clinically significant anxiety as defined by a score of 5 or greater on the GAD-7; * 1/4 the participants (n=10) will be those with low anxiety as defined by a GAD-7 score of \<5. Exclusion Criteria: * Presence of chronic mental or physical illness (except for anxiety) * History of allergies, autoimmune, liver, or other severe chronic diseases * Current and regular use of prescription medications such as steroids, non-steroid anti-inflammatory drugs, aspirin, immune modifying drugs, opioid analgesics, statins, antihypertensive drugs, anti-arrhythmic drugs, and antidepressant medications (none in the last 6 months) * Nightshift work or time zone shifts (\> 3hrs) within the previous 6 weeks * Previous history of fainting during blood draws. * Claustrophobia * Metal in the body * Presence of co-morbid medical conditions not limited to but including cardiovascular (e.g., history of acute coronary event, stroke) and neurological diseases (e.g., Parkinson's disease), as well as pain disorders; * Presence of comorbid inflammatory disorders such as rheumatoid arthritis or other autoimmune disorders; * Presence of an uncontrolled medical condition that is deemed by the investigators to interfere with the proposed study procedures, or to put the study participant at undue risk; * Presence of chronic infection, which may elevate pro-inflammatory cytokines; * Presence of an acute infectious illness in the two weeks prior to an experimental session. * Current Axis I psychiatric disorders other than anxiety as determined by the Research Version of the Structured Clinical Interview * Lifetime history of suicide attempt or inpatient psychiatric admission. * Sleep Disorders: Current history of sleep apnea or nocturnal myoclonus; * Phase-shift disorder * Current and/or past regular use of hormone-containing medications including steroids; * Current and/or past regular use of non-steroid anti-inflammatory drugs; * Current and/or past regular use of immune modifying drugs that target specific immune responses such as cytokine antagonists; * Current and/or past regular use of analgesics such as opioids; * Current and/or past regular use of cardiovascular medications, including antihypertensive, anti-arrhythmic, antianginal, and anticoagulant drugs; * Current smoking * Current excessive caffeine use (\>600 mg/day) because of the known effects on pro-inflammatory cytokine levels; * Evidence of recreational drug use from urine test. * Body mass index \> 35 because of the effects of obesity on proinflammatory cytokine activity * Any clinically significant abnormality on screening laboratory tests * Clinically significant abnormalities in electrocardiogram

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Norman Cousins Center for Psychoneuroimmunology, University of California, Los Angeles

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.